Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan

The complement component C5 inhibitory peptide zilucoplan is currently in phase III clinical trials for myasthenia gravis (MG). Despite being at an advanced stage of clinical development, there have been no published reports in the literature detailing its chemical synthesis. In this work, we descri...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorman, Declan M., Lee, John, Payne, Colton D., Woodruff, Trent M., Clark, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781173/
https://www.ncbi.nlm.nih.gov/pubmed/33398524
http://dx.doi.org/10.1007/s00726-020-02921-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781173/
https://www.ncbi.nlm.nih.gov/pubmed/33398524
http://dx.doi.org/10.1007/s00726-020-02921-5

Ejemplares similares